Navigation Links
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
Date:10/18/2007

one marrow and spleen, so selecting targets in these tissues is part of our strategy for developing effective drugs. We plan to move ISIS 388626 forward toward human proof-of-concept as rapidly as possible, and we look forward to continuing to populate our metabolic disease pipeline with drugs arising from our prolific research program."

ABOUT SGLT2 AND ISIS 388626

The sodium dependent glucose transporter type 2 (SGLT2) is substantially responsible for glucose re-absorption in the kidney. Decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive target for the treatment of diabetes. In preclinical studies, Isis has demonstrated in several animal species that ISIS 388626 and other antisense inhibitors of SGLT2 effectively reduce target mRNA levels, increase urinary glucose excretion and consequently lower blood glucose levels and HbA1c without causing dangerously low levels of blood sugar known as hypoglycemia. This is consistent with expectations based on human subjects who have mutations in the SGLT2 gene and have increased urine glucose levels but are otherwise asymptomatic. ISIS 388626 effectively and specifically inhibits the production of SGLT2 in the kidney tissue, without having any effect on a related gene product, SGLT1. In addition to being Isis' first second-generation antisense drug for a kidney target, ISIS 388626 is also unique due to its 12 nucleotide length rather than the more typical 18 - 21 nucleotide sequences that comprise Isis' other drugs. This attribute simplifies manufacturing and has the potential to substantially reduce related expenses. The short sequence may also contribute to ISIS 388626's unusually high potency; it is among the most potent antisense drugs Isis has yet evaluated in preclinical models.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The C
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Cancer drugs in development nearly doubled since 1995
3. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
4. Role of zinc in development
5. Particulate matter affects lung development
6. Fossil teeth and human development
7. High development costs hinder entry of cancer super drugs into the market
8. Fireflies help speed development of new drugs
9. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
10. New fertility drug development techniques by Organon
11. Biosensor chip to help drug development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
(Date:3/5/2015)... 2015 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today it will report fourth ... open on Wednesday, March 25, 2015, followed by ... Eastern. Conference Call & Webcast: ... Domestic: , 800-753-9057International: , 913-981-5571Conference ID: , ...
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März ... Gates Stiftung und das deutsche biopharmazeutische Unternehmen ... 46 Millionen Euro (52 Millionen US-Dollar) in ... Bereich der medizinisch angewandten Messenger-RNA (mRNA). Auf ... Ansätze zur Behandlung von Krankheiten und zum ...
(Date:3/5/2015)...  As the pharmaceutical industry works to address ... professionals are placing a significant emphasis on company ... by LRN, the leader in Ethics & Compliance ... respondents expressed that clarity on company values is ... training programs (57%), trumping understanding of the PhRMA ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... 2010 Results from the VeriStrat analysis of a ... with sorafenib in patients with advanced non-small cell lung ... Symposium on Molecular Targets in Cancer Therapeutics being held ... the VU Medical Center, Amsterdam, The Netherlands.  The intention ...
... SAN DIEGO, Nov. 19, 2010 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel anti-cancer therapeutics, announced today ... the Listing Qualifications Staff of The NASDAQ Stock Market ... $10 million stockholders, equity requirement for continued listing on ...
Cached Medicine Technology:VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 2VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 3Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 2Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: